Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery

References

• Adelli G, Srirangam R, Majumdar S. (2013). Phytochemicals in ocular health: therapeutic potential and delivery challenges. World J Pharmacol 2:18–34
   Google Scholar
• Adelli GR, Hingorani T, Punyamurthula N, et al. (2015). Evaluation of topical hesperetin matrix film for back-of-the-eye delivery. Eur J Pharm Biopharm 92:74–82
   PubMed Web of Science ®Google Scholar
• Agarwal R, Iezhitsa I, Agarwal P, et al. (2016). Liposomes in topical ophthalmic drug delivery: an update. Drug Deliv 23:1075–91
   PubMed Web of Science ®Google Scholar
• Amsel LP, Hinsvark ON, Raghunathan Y. (1980). Reoc Res Sci Dev Conf, Washington DC: Proprietary Association, 94
   Google Scholar
• Bausch & Lomb Incorporated. 0.1% Diclofenac sodium Ophthalmic solution PI_Bausch.and.Lomb_Diclofenac_Sodium_Ophthalmic_Solution_11-2012.pdf
   Google Scholar
• Betoptic S® (Betaxolol Hydrochloride Ophthalmic Suspension). Available at: http://www.rxlist.com/betoptic-s-drug.htm
   Google Scholar
• Bhise K, Shaikh S, Bora D. (2008). Taste mask, design and evaluation of an oral formulation using ion exchange resin as drug carrier. AAPS PharmSciTech 9:557–62
   PubMed Web of Science ®Google Scholar
• Blanco FJ, Guitian R, Moreno J, et al. (1999). Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol 26:1366–73
   PubMed Web of Science ®Google Scholar
• Boyd GE, Adamson AW, Myers Jr LS. (1947). The exchange adsorption of ions from aqueous solutions by organic zeolites; kinetics. J Am Chem Soc 69:2836–48
   PubMed Web of Science ®Google Scholar
• Chaudhry NC, Saunders L. (1956). Sustained release of drugs from ion exchange resins. J Pharm Pharmacol 8:975–83; discussion 983–6
   PubMed Web of Science ®Google Scholar
• Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. (2010). Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 51:5403–20
   PubMed Web of Science ®Google Scholar
• Fawzi AA, Fong DS, Michels R, et al. (2005). Drugs in ophthalmology: Berlin-Heidelberg: Springer
   Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. (2010). Ocular drug delivery. AAPS J 12:348–60
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. (2000). Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 41:961–4
   PubMed Web of Science ®Google Scholar
• Guo X, Chang RK, Hussain MA. (2009). Ion-exchange resins as drug delivery carriers. J Pharm Sci 98:3886–902
   PubMed Web of Science ®Google Scholar
• Halder A, Sa B. (2006). Sustained release of propranolol hydrochloride based on ion-exchange resin entrapped within polystyrene microcapsules. J Microencapsul 23:899–911
   PubMed Web of Science ®Google Scholar
• Herbort CP, Jauch A, Othenin-Girard P, et al. (2000). Diclofenac drops to treat inflammation after cataract surgery. Acta Ophthalmol Scand 78:421–4
   PubMedGoogle Scholar
• Honda M, Asai T, Oku N, et al. (2013). Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine 8:495–503
   PubMed Web of Science ®Google Scholar
• Jani R, Gan O, Ali Y, et al. (1994). Ion exchange resins for ophthalmic delivery. J Ocul Pharmacol 10:57–67
   PubMedGoogle Scholar
• Jeong SH, Berhane NH, Haghighi K, Park K. (2007). Drug release properties of polymer coated ion-exchange resin complexes: experimental and theoretical evaluation. J Pharm Sci 96:618–32
   PubMed Web of Science ®Google Scholar
• Kankkunen T, Huupponen I, Lahtinen K, et al. (2002). Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 16:273–80
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. (2002). Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28:473–93
   PubMed Web of Science ®Google Scholar
• Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. (2013). Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 36:172–98
   PubMed Web of Science ®Google Scholar
• Lee VH, Robinson JR. (1986). Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 2:67–108
   PubMedGoogle Scholar
• Lee YC, Millard J, Negvesky GJ, et al. (1999). Formulation and in vivo evaluation of ocular insert containing phenylephrine and tropicamide. Int J Pharm 182:121–6
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Z, Chen H. (2013). Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int J Pharm 448:96–100
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Z, Li J, et al. (2012). Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 4:4667–73
   PubMed Web of Science ®Google Scholar
• Liang R, Luo Z, Pu G, et al. (2016). Self-assembled peptide-based supramolecular hydrogel for ophthalmic drug delivery. RSC Advances 6:76093–8
   Web of Science ®Google Scholar
• Maichuk Iu F, Iuzhakov AM. (1994). [Ocular therapeutic films: long-term results and perspectives of use]. Med Tekh 2:34–6
   PubMedGoogle Scholar
• Majumdar S, Hingorani T, Srirangam R, et al. (2009). Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res 26:1261–9
   PubMed Web of Science ®Google Scholar
• Majumdar S, Hingorani T, Srirangam R. (2010). Evaluation of active and passive transport processes in corneas extracted from preserved rabbit eyes. J Pharm Sci 99:1921–30
   PubMed Web of Science ®Google Scholar
• Majumdar S, Srirangam R. (2009). Solubility, stability, physicochemical characteristics and in vitro ocular tissue permeability of hesperidin: a natural bioflavonoid. Pharm Res 26:1217–25
   PubMed Web of Science ®Google Scholar
• Mantell CL. (1951). Ion Exchangers. Adsorption: McGraw-Hill; 185–216
   Google Scholar
• Maulvi FA, Soni TG, Shah DO. (2016). A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv 23:3017–26
   PubMed Web of Science ®Google Scholar
• Ove F, Stefan L, Claes L, (1975). Chewable smoking substitute composition. Sweden Aktiebolaget Leo, Helsingborg, Sweden. Appl. No.: 497,557. United States Patent US3901248 A.
   Google Scholar
• Patra S, Samantaray R, Pattnaik S, Barik BB. (2010). Taste masking of Etoricoxib by using ion-exchange resin. Pharm Dev Technol 15:511–17
   PubMed Web of Science ®Google Scholar
• Sasaki H, Nagano T, Sakanaka K, et al. (2003). One-side-coated insert as a unique ophthalmic drug delivery system. J Control Release 92:241–7
   PubMed Web of Science ®Google Scholar
• Sharma OP, Patel V, Mehta T. (2016). Nanocrystal for ocular drug delivery: hope or hype. Drug Deliv Transl Res 6:399–413
   PubMed Web of Science ®Google Scholar
• Sriwongjanya M, Bodmeier R. (1998). Effect of ion exchange resins on the drug release from matrix tablets. Eur J Pharm Biopharm 46:321–7
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. (2015). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51
   PubMed Web of Science ®Google Scholar
• Swaminathan J, Ehrhardt C. (2012). Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv 9:1489–503
   PubMed Web of Science ®Google Scholar
• The Dow Chemical Company. Applications for AMBERLITE™ & DUOLITE™ ion exchange resins: drug formulation applications of dow ion exchange resins [online]. Available at: http://pharmaandfood.dow.-com/en/pharma-solutions/products/amberlite-and-uolite/applications
   Google Scholar
• The Dow Chemical Company. (2013). Introduction & ion exchange principles. Dow Amberlite™ and Duolite™ ion exchange resin excipients. Handling and Use Guide, 6-7
   Google Scholar
• Wang X, Wang S, Zhang Y. (2016). Advance of the application of nano-controlled release system in ophthalmic drug delivery. Drug Deliv 23:2897–2901
   PubMed Web of Science ®Google Scholar